Affiliation:
1. North-Western State Medical University named after I.I. Mechnikov, Ministry of Health of Russia
Abstract
The article describes a clinical case of systemic lupus erythematosus (SLE) resistant to traditional treatment regimens and the first successful experience with the type I interferon inhibitor – anifrolumab, as part of an early access program in the Russian Federation. High efficacy and safety of the drug in the treatment of SLE with active lesions of the skin, mucous membranes and joints were noted.
Subject
Pharmacology (medical),Immunology,Immunology and Allergy,Rheumatology
Reference18 articles.
1. Mazurov VI, editor. Clinicheskaya revmatologia.. Rukovodstvo dlya vrachei [Clinical rheumatology. Guide for doctors]. 3rd edition. Moscow: E-noto; 2021 696 p.
2. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J Autoimmun. 2019 Jan;96:1-13. doi: 10.1016/j.jaut.2018.11.001. Epub 2018 Nov 16.
3. Gaidukova IZ, Mazurov VI, Inamova OV, et al. Disease activity and comorbidities in patients with systemic lupus erythematosus — what has changed in two decades? Russkii meditsinskii zhurnal. 2021;(1):2-6. (In Russ.).
4. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089.
5. Zahr ZA, Fang H, Magder LS, Petri M. Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort. Lupus. 2013 Jun;22(7):697-701. doi: 10.1177/0961203313490434. Epub 2013 May 24.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献